Zigma 300mg Tablet CR contains Carbamazepine, an anticonvulsant and mood-stabilizing agent primarily indicated for the management of epilepsy, trigeminal neuralgia, and bipolar disorder. This controlled-release formulation ensures a sustained therapeutic plasma concentration, enhancing patient compliance by reducing dosing frequency. Carbamazepine acts by stabilizing hyperexcited nerve membranes, inhibiting repetitive neuronal discharges, and reducing synaptic propagation of excitatory impulses. It is effective in controlling partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizure patterns. Additionally, Carbamazepine demonstrates efficacy in alleviating neuropathic pain associated with trigeminal neuralgia and in the prophylactic treatment of manic and depressive episodes in bipolar disorder. The controlled-release mechanism minimizes peak-trough fluctuations, potentially reducing adverse effects such as dizziness, drowsiness, nausea, and ataxia. Dosage must be individualized based on clinical response and tolerability, with gradual titration recommended to mitigate side effects. Regular monitoring of hematologic parameters, liver function, and serum drug levels is advised to detect potential toxicity or hypersensitivity reactions. Zigma 300mg Tablet CR should be used under strict medical supervision, considering possible drug interactions and contraindications, particularly in patients with a history of bone marrow depression, cardiac conduction abnormalities, or hypersensitivity to Carbamazepine or related compounds.